We're taking a closer look at the new FDA regulation of COVID vaccines. We brought this to you yesterday reporting that updated COVID vaccines are no longer recommended for healthier adults and ...

May 27 (Reuters) - The U.S. FDA has paused Rocket Pharmaceuticals' (RCKT.O), opens new tab mid-stage gene therapy trial after a patient died from serious complications, the drug developer said on ...

Compounding pharmacies had been producing these off-brand versions under special allowances due to shortages of the FDA-approved medications. Since the FDA declared the shortages over, these ...

The FDA on Tuesday held a panel discussion on the alleged risks of talcum powder. Talc, an anti-caking agent that is mined from rock, is prevalent in food and pharmaceutical products. Plaintiff ...

Perspective from Jade Coats, OD, FAAO The FDA cleared an investigational new drug application for a phase 2 trial of GRF312 ophthalmic solution, an immunoglobulin eye drop for the treatment of dry ...

A rubber-stamping approach to approving COVID boosters perpetuity without updated clinical trial data under the Biden administration is now over.” The anticipated new guidance from the FDA comes ...

Former FDA leader Janet Woodcock, M.D., is also on the CTAC’s board, along with Big Pharma vet Freda Lewis-Hall, M.D., who most recently spent 11 years at Pfizer. The CTAC spent its trial period ...

But FDA Commissioner Dr. Martin Makary and FDA vaccine ... Since the COVID-19 virus can mutate quickly, a lengthy clinical trial may result in a vaccine that no longer protects against currently ...

The Food and Drug Administration (FDA) says it’s only prioritizing covid vaccine approvals for adults older than 65 and others over the age of 6 months who have at least one “risk factor ...

--(BUSINESS WIRE)--Atia Vision, Inc., a Shifamed portfolio company, today announced it has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA ...

He highlighted the FDA's clearance to initiate the trial as "a significant milestone, bringing us closer to commencing patient enrollment." Lebovits emphasized that the trial design has been ...